High B-cell-activating factor levels in endemic Tunisian pemphigus

Sir,

B-cell-activating factor belonging to the tumor necrosis factor family plays a crucial role in B-cell development, immunoglobulin production and switch to the IgG, IgE and IgA subclasses. Excessive B-cell-activating factor rescues self-reactive B cells from anergy which may play a crucial role in the induction and development of autoimmunity. Previous reports have shown elevated serum B-cell-activating factor levels in patients with systemic lupus, Sjögren syndrome and rheumatoid arthritis.1

Pemphigus is an autoimmune intraepidermal blistering disease characterized by the presence of autoantibodies against desmoglein 1 in pemphigus foliaceus and desmoglein 3 in pemphigus vulgaris. Knowing that B-cell-activating factor pathway is involved in the generation of autoreactive B cells, we analyzed serum B-cell-activating factor levels in Tunisian pemphigus vulgaris and pemphigus foliaceus patients and correlated their levels with immunological criteria of pemphigus. Forty pemphigus foliaceus and 28 pemphigus vulgaris patients. Among pemphigus patients with recurrent, active disease, 9 pemphigus foliaceus and 14 pemphigus vulgaris patients were under systemic therapy at the time of drawing the blood to perform serum B-cell-activating factor measurement. The retrospective nature of the study limited the clinical data concerning severity of the diseases for 27 pemphigus foliaceus and 28 pemphigus vulgaris patients from the case records. For these patients, we evaluated the severity of pemphigus according to the cutaneous and mucosal involvement of defined areas of the body – score 0 (no lesions), score 1 (<25% involvement), score 2 (25%–50%), score 3 (50%–75%) and score 4 (>75%). Thirty eight healthy controls with a median age of 43 years were also recruited in the study.

This investigation was approved by the ethical committee of La Rabta University Hospital. All patients and controls gave their consents for the study.

Pemphigus foliaceus and pemphigus vulgaris patients as well as healthy control were already tested for anti-desmoglein 1 and 3 autoantibodies (MBL, Nagoya, Japan) and the presence of autoantibodies other than anti-desmoglein.2

A specific enzyme-linked immunosorbent assay kit was used to measure serum B-cell-activating factor levels (R&D Systems Inc., Minneapolis, USA). Values above the mean ± 2 standard deviation (1168 pg/ml) in control samples were considered as high levels.

References

1. Goodfield MJ, Jones SK, Veale DJ. Systemic sclerosis. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook’s Textbook of Dermatology. 8th ed. Oxford: Blackwell Scientific Publications; 2004.
2. Laragh JH. Reversal of vascular and renal crises of scleroderma by oral angiotensin‑converting‑enzyme blockade. N Engl J Med 1979;300:1417‑9.
3. Viswanth V, Sonavane AD, Doshi AC, Parab MG. Dexamethasone – cyclophosphamide pulse in the generation of autoreactive B cells, we analyzed serum B-cell-activating factor levels in patients with systemic lupus, Sjögren syndrome and rheumatoid arthritis.1
4. Lopez‑Ovejero JA, Saal SD, D’Angelo WA, Cheigh JS, Stenzel KH, et al. Late aortic insufficiency: clinical presentation and autoantibody profile.2
5. Pasricha JS, Ramam M. Variations of modifications of the standard regimen. In: Pasricha JS, editor. Pulse Therapy in Pemphigus and Other Diseases. 3rd ed. New Delhi: Mehta Publishers; 2006. p. 124‑7.
6. Pasricha JS, Ramam M. Variations of modifications of the standard regimen. In: Pasricha JS, editor. Pulse Therapy in Pemphigus and Other Diseases. 3rd ed. New Delhi: Mehta Publishers; 2006. p. 91‑116.
7. Das S, Giri PP, Roy AK. Dexamethasone‑cyclophosphamide pulse in patients as well as 29 pemphigus vulgaris patients had recurrent, active disease; the other patients were in remission. Blood sample was collected before corticosteroid treatments in 28 pemphigus foliaceus and 22 pemphigus vulgaris patients. Among pemphigus foliaceus and pemphigus vulgaris patients were under systemic therapy at the time of drawing the blood to perform serum B-cell-activating factor measurement. The retrospective nature of the study limited the clinical data concerning severity of the diseases for 27 pemphigus foliaceus and 28 pemphigus vulgaris patients from the case records. For these patients, we evaluated the severity of pemphigus according to the cutaneous and mucosal involvement of defined areas of the body – score 0 (no lesions), score 1 (<25% involvement), score 2 (25%–50%), score 3 (50%–75%) and score 4 (>75%). Thirty eight healthy controls with a median age of 43 years were also recruited in the study.

This investigation was approved by the ethical committee of La Rabta University Hospital. All patients and controls gave their consents for the study.

Pemphigus foliaceus and pemphigus vulgaris patients as well as healthy control were already tested for anti-desmoglein 1 and 3 autoantibodies (MBL, Nagoya, Japan) and the presence of autoantibodies other than anti-desmoglein.2

A specific enzyme-linked immunosorbent assay kit was used to measure serum B-cell-activating factor levels (R&D Systems Inc., Minneapolis, USA). Values above the mean ± 2 standard deviation (1168 pg/ml) in control samples were considered as high levels.
Statistical analysis was performed using the Statistical Package for Social Sciences, version 16.0 (SPSS Inc., Chicago, IL, USA). $P < 0.05$ was considered statistically significant.

In healthy control, serum B-cell-activating factor levels ranged between 200 and 1200 pg/ml with a mean value of 748 ± 206 pg/ml. Serum B-cell-activating factor mean values did not differ between the three groups (pemphigus foliaceus, pemphigus vulgaris and healthy control), yet we note a $P$ value ($P = 0.052$) near the threshold of significance. However, after Bonferroni correction, serum B-cell-activating factor levels were significantly higher in pemphigus foliaceus patients (mean level $982 ± 557$ pg/ml) than in healthy control, $P = 0.046$. There was no statistically significant difference between pemphigus vulgaris patients and healthy control [Figure 1].

High serum B-cell-activating factor levels were observed in 14 (28%) pemphigus foliaceus and 11 (30.5%) pemphigus vulgaris patients.

In pemphigus foliaceus patients, serum B-cell-activating factor levels were significantly higher in those without corticosteroid treatment (mean level $1229 ± 573$ pg/ml) than in healthy control ($P < 0.001$ by $t$-test). Moreover, mean serum B-cell-activating factor levels were significantly higher in patients with high score disease severity ($P = 0.012$ by $t$-test) and in those with the recurrent active disease before re-introduction of corticosteroid or any other treatment ($P < 0.001$ by $t$-test) [Table 1].

In pemphigus foliaceus patients, scores for disease severity were available for seven and twenty cases with high and low serum B-cell-activating factor, respectively. Among the seven pemphigus foliaceus patients with high serum B-cell activating factor, all (100%) had widespread disease (score of disease severity 3–4) compared to nine of twenty patients (45%) in those with normal serum B-cell-activating factor ($P = 0.02$ by Fisher’s exact test).

In pemphigus vulgaris patients, scores for disease severity were available for 7 and 21 cases with high and low serum B-cell-activating factor, respectively. Among the seven pemphigus vulgaris patients with high serum B-cell activating factor, only 4 (57%) showed severe lesions compared to 6 of 21 (28%) of those with normal serum B-cell-activating factor.

Although serum B-cell-activating factor levels did not correlate with age, stratification of patients according to the mean age revealed that younger pemphigus foliaceus patients had significantly higher levels.

In both groups, there was no significant correlation between serum B-cell activating factor neither with anti-desmoglein 1/desmoglein 3 autoantibodies titers nor with the presence of autoantibodies other than anti-desmoglein.

Unlike previous studies, our findings revealed the presence of a significant difference among autoimmune pemphigus patients and controls.$^{3,4}$

Matsushita et al. did not find a significant difference between pemphigus or pemphigoid patients and the control group regarding serum B-cell-activating factor levels.$^2$ Asashima et al. reported a significant difference in bullous pemphigoid, but not in pemphigus vulgaris patients.$^4$ In this study, we found that serum B-cell activating factor values were significantly higher in pemphigus foliaceus patients than in healthy control. Interestingly, significant associations between serum B-cell-activating factor values, younger age and clinical status (absence of corticosteroid treatment and disease activity) were found only in the pemphigus foliaceus group. In Tunisia, pemphigus has particular epidemiological features: pemphigus foliaceus is the endemic form of the disease; it is predominantly observed in women of the reproductive age group. These patients have common human leukocyte antigen susceptibility alleles which vary from the ones observed in the sporadic form in the north of the country.$^3$ Thus, B-cell activating factor elevation occurs mainly in patients with Tunisian endemic pemphigus features.

Serum B-cell activating factor mean levels were found to be significantly lower in patients under corticosteroid treatment. This effect is different from that seen in rituximab-treated patients.$^6$ In this study, we failed to find a significant correlation between anti-desmoglein 1/desmoglein 3 autoantibodies titers and serum B-cell-activating factor, while in systemic lupus erythematosus, a strong association was found between anti-deoxyribonucleic acid antibodies titers and serum B-cell-activating factor values. Moreover, serum B-cell-activating factor levels in Tunisian systemic lupus erythematosus cases are significantly higher compared to those found in Tunisian pemphigus foliaceus patients $(2340.72 ± 1000$ pg/ml, unpublished data).

The presence of high levels of serum B-cell-activating factor suggests that this cytokine induces the expansion of activated B and T cells and autoantibodies production. This overexpression, significantly observed in the absence of treatment mainly on the earlier onset of pemphigus foliaceus, suggests that serum B-cell-activating factor participated in the proliferation of autoreactive cells, thus enhancing the autoimmune response. Besides, it has been reported that B-cell-activating factor acts on dendritic cells helping them to increase the pro-inflammatory activity of T cells. This is in accordance with the association of high serum B-cell-activating factor levels with high score disease in pemphigus foliaceus. This data may reflect serum B-cell-activating factor contributing to pemphigus pathogenesis.

Interestingly, B-cell-activating factor polymorphism $-871C/T$ is involved in pemphigus foliaceus pathogenesis.$^7$ The association of this polymorphism in our patients and assessing its functional impact are needed to investigate the biological
Letters to the Editor

Table 1: Mean serum B-cell-activating factor levels according to clinical characteristics of pemphigus patients

| Characteristic                        | Group       |           |           |           |           | P        |
|---------------------------------------|-------------|-----------|-----------|-----------|-----------|----------|
|                                       | PF          | PV        | HC        |           |           |          |
|                                       | n           | Mean±SD   | n          | Mean±SD   | n          | Mean±SD  |
| Overall                               | 50          | 982±557   | 36         | 875±441   | 38         | 748±206  | 0.046    |
| Recurrent disease                     |             |           |           |           |           |          |
| No                                    | 6           | 885±278   | 7          | 871±421   | -          | 0.65     |
| Yes                                   | 40          | 988±605   | 29         | 876±453   | -          |          |
| P                                      | 0.59        |           | 0.78      |           |           |          |
| Corticosteroids                       |             |           |           |           |           |          |
| No                                    | 28          | 1229±753  | 14         | 885±445   | -          | 0.003    |
| Yes                                   | 22          | 668±343   | 22         | 859±450   | -          |          |
| P                                      | 0.001       |           | 0.86      |           |           |          |
| Active disease and steroids           |             |           |           |           |           |          |
| No corticosteroids and no relapse     | 1           | 1332      | 2          | 491±70    | -          | 0.09     |
| No corticosteroids and active disease | 26          | 1258±593  | 20         | 924±448   | -          |          |
| Corticosteroids and no relapse        | 5           | 796±191   | 4          | 985±458   | -          |          |
| Corticosteroids and active disease    | 14          | 574±290   | 9          | 768±470   | -          |          |
| P                                      | 0.6         | 0.04      | 0.49      |           |           |          |
| Disease score                         |             |           |           |           |           |          |
| 0-2                                   | 11          | 718±248   | 18         | 707±362   | -          | 0.022    |
| 3-4                                   | 16          | 1177±517  | 10         | 1012±567  | -          |          |
| P                                      | 0.001       |           | 0.93      |           |           |          |
| Age                                   |             |           |           |           |           |          |
| Less than mean age                    | 19          | 1216±701  | 11         | 694±395   | 24         | 751±220  | 0.011    |
| More than mean age                    | 31          | 839±395   | 25         | 974±444   | 14         | 679±203  |          |
| P                                      | 0.018       |           | 0.104     |           | 0.24      |          |
| Duration of disease                   |             |           |           |           |           |          |
| <1 month                              | 31          | 1070±647  | 25         | 873±485   | -          | 0.61     |
| >1 month and <1 year                  | 2           | 620±128   | 2          | 669±345   | -          |          |
| >1 year                               | 9           | 917±312   | 9          | 926±339   | -          |          |
| P                                      | 0.26        |           | 0.56      |           |           |          |

*Significant p value with the PF group compared to HC. SD: Standard deviation, PF: Pemphigus foliaceus, PV: Pemphigus vulgaris, HC: Healthy controls

The significance of serum B-cell-activating factor elevation in pemphigus foliaceus patients. Targeting B-cell-activating factor with monoclonal antibodies (belimumab) has been approved for systemic lupus erythematosus treatment, but clinical and theoretical arguments for a potential beneficial effect in pemphigus are lacking.6

In conclusion, we described the presence of higher levels of serum B-cell-activating factor in pemphigus foliaceus patients. These levels correlated with disease activity in patients without treatment. Because this finding is mainly observed in patients with features of the endemic form of Tunisian pemphigus foliaceus, it needs to be confirmed in other endemic forms of pemphigus within homogeneous and comparable age repartition and disease duration. Answering this question will clarify whether the autoimmune mechanisms through serum B-cell-activating factor varies among pemphigus forms and possibly making the endemic forms distinct.

Acknowledgment

This work was supported by research grant from University of Tunis El Manar to “Immuno-Rheumatology laboratory ” La Rabta Hospital, 1007 Tunis, Tunisia.

Financial support and sponsorship

The study was supported by grants by from Tunis El Manar University, The Tunisian ministry of higher education and scientific research (LR05SP01).

Conflicts of interest

There are no conflicts of interest.

Kaouthar Mejri, Maryam Kallel Sellami, Ines Rania Zarar1, Lilia Laadhar, Houria Lahmar, Mourad Mokni1, Insaf Mokhtar2, Bacima Fezza3, Mondher Zitouni, Sondes Makni

Departments of Immunology and 1Dermatology, La Rabta Hospital, 2Department of Dermatology, Habib Thameur Hospital, 3Department of Dermatology, Charles Nicolle Hospital, Tunis, Tunisia

Correspondence: Dr. Maryam Kallel Sellami, Department of Immunology, La Rabta Hospital, Tunis 1007, Tunisia. E-mail: maryam_kallel@yahoo.com
Elevated serum BAFF levels in patients with immune deficiency syndrome control organization guideline. Once an easily treatable disease, it has been reported that.

Penicillinase production confirmation through Hodge test. Letters to the Editor.

Hodge test was carried out among the resistant phenotypes. Modified disc diffusion methods. Modified nalidixic acid, azithromycin, spectinomycin and ceftriaxone susceptibility testing was done as per standard protocol.

Antimicrobial susceptibility testing was done using polymerase chain reaction. Immune deficiency syndrome control organization guideline.

Screening was done using polymerase chain reaction. The study was conducted at Agartala Government Medical College, Agartala, Tripura, between July 2013 and June 2015 after receiving clearance from the institutional ethical committee. Two hundred and seventy five subjects suspected to have clinically compatible features of sexually transmitted infections in the reproductive age group of 18–49 years attending the dermatology or the obstetrics and gynecology outpatient department were included in the study. The controls were 100 non-smoking healthy subjects of the same age group.

One hundred and ninety two (70%) subjects were males and 88 (30%) were females. The mean age of the study subjects was 25.58 ± 6.06 years. The mean age of the control group was 25.57 ± 5.58 years.

The study group was further divided into three groups according to the duration of disease: recent group (≤1 year; n = 100), intermediate group (1–3 years; n = 100), and long-term group (>3 years; n = 75). The study group was also divided into three groups according to the extent of disease: mild group (n = 50), moderate group (n = 100), and severe group (n = 75).

A total of 655 Neisseria gonorrhoeae isolates were collected from the study and control groups. Neisseria gonorrhoeae was isolated from the genitalia of the study group and the controls.

Given that gonococcal infection is caused by the Gram-negative diplococcus Neisseria gonorrhoeae in the developed world caused by the Gram-negative diplococcus Neisseria gonorrhoeae. Sir, circulating in Tripura endemic Tunisian pemphigus foliaceus is associated with the HLA-DR3 gene: Anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. Br J Dermatol 2009;161:522-7.

Serum levels of BAFF are increased in bullous pemphigoid patients. Induced systemic lupus erythematosus. A critical review of clinical trials in systemic lupus erythematosus.

Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. Br J Dermatol 2009;160:2202-10.

Individual and epistatic effects of genetic polymorphisms of B-cell co-stimulatory molecules on susceptibility to pemphigus foliaceus. Genes Immun 2009;10:547-58.

A critical review of clinical trials in systemic lupus erythematosus. Lupus 2016;25:1122-40.

References
1. Moisini I, Davidson A. BAFF: A local and systemic target in autoimmune diseases. Clin Exp Immunol 2009;158:155-63.
2. Matsushita T, Hasegawa M, Matsushita Y, Echigo T, Wayaku T, Horikawa M, et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 2007;16:87-93.
3. Mejri K, Abida O, Kallel-Sellami M, Haddouk S, Laadhar L, Zarraa IR, et al. Spectrum of autoantibodies other than anti-desmoglein in pemphigus patients. J Eur Acad Dermatol Venereol 2011;25:774-81.
4. Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H, et al. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol 2006;155:330-6.
5. Abida O, Zitouni M, Kallel-Sellami M, Mahfoudh N, Kammoun A, Ben Ayed M, et al. Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: Anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. Br J Dermatol 2009;161:522-7.
6. Nagel A, Podstawa E, Eickmann M, Müller HH, Hertl M, Eming R. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009;129:2202-10.
7. Malheiros D, Petzl-Erler ML. Individual and epistatic effects of genetic polymorphisms of B-cell co-stimulatory molecules on susceptibility to pemphigus foliaceus. Genes Immun 2009;10:547-58.
8. Mahieu MA, Strand V, Simon LS, Lipsky PE, Ramsey-Goldman R. A critical review of clinical trials in systemic lupus erythematosus. Lupus 2016;25:1122-40.

How to cite this article: Mejri K, Sellami MK, Zarraa IR, Laadhar L, Lahmar H, Mokni M, et al. High B-cell-activating factor levels in endemic Tunisian pemphigus. Indian J Dermatol Venereol Leprol 2017;83:496-9.